A carregar...
Treating Advanced Unresectable or Metastatic HER2-Positive Breast Cancer: A Spotlight on Tucatinib
The management of HER2 positive breast cancer has been transformed by the development of targeted therapies. Dual blockade with the monoclonal antibodies, trastuzumab and pertuzumab, added to first-line taxane chemotherapy and second-line therapy with the antibody–drug conjugate, T-DM1, are internat...
Na minha lista:
| Publicado no: | Breast Cancer (Dove Med Press) |
|---|---|
| Main Authors: | , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
Dove
2021
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC8164963/ https://ncbi.nlm.nih.gov/pubmed/34079368 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2147/BCTT.S268451 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|